Summary
Cytokine therapy has been extensively investigated in the treatment of malignancies. However, only a few agents, such as interferon and interleukin-2, have proven to have sufficient clinical benefit to justify their more widespread use. This chapter reviews the biology and clinical data for cytokine-based therapies that have been approved for clinical use, as well as cytokines that are currently under investigation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kaplan, D.H., et al., Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA, 1998. 95(13): p. 7556–61.
Picaud, S., et al., Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res, 2002. 22(4): p. 457–62.
Shankaran, V., et al., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 2001. 410(6832): p. 1107–11.
Street, S.E., E. Cretney, and M.J. Smyth, Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood, 2001. 97(1): p. 192–7.
Street, S.E., et al., Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med, 2002. 196(1): p. 129–34.
Abbas, A.K., A.H. Lichtman, and J.S. Pober. Cellular and Molecular Immunology. W.B. Saunders company; Philadelphia, PA 19103 4th edition (May 15, 2000).
Pestka, S., C.D. Krause, and M.R. Walter, Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 2004. 202: p. 8–32.
Pestka, S., et al., Interferons and their actions. Annu Rev Biochem, 1987. 56: p. 727–77.
Stewart, W.E., 2nd, Interferon nomenclature recommendations. J Infect Dis, 1980. 142(4): p. 643.
Isaacs, A. and J. Lindenmann, Virus interference. I. The interferon. J Interferon Res, 1987. 7(5): p. 429–38.
Muller, U., et al., Functional role of type I and type II interferons in antiviral defense. Science, 1994. 264(5167): p. 1918–21.
Basham, T.Y., et al., Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc Natl Acad Sci USA, 1982. 79(10): p. 3265–9.
Dolei, A., M.R. Capobianchi, and F. Ameglio, Human interferon-gamma enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-alpha and interferon-beta. Infect Immun, 1983. 40(1): p. 172–6.
Herberman, R.B., et al., Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol, 1982. 67(1): p. 160–7.
Ortaldo, J.R., et al., Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer, 1983. 31(3): p. 285–9.
Ortaldo, J.R., et al., Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem, 1983. 258(24): p. 15011–5.
Wagner, T.C., et al., Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer, 2004. 111(1): p. 32–42.
Clemens, M.J., Interferons and apoptosis. J Interferon Cytokine Res, 2003. 23(6): p. 277–92.
Sidky, Y.A. and E.C. Borden, Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res, 1987. 47(19): p. 5155–61.
Tsuruoka, N., et al., Inhibition of in vitro angiogenesis by lymphotoxin and interferon-gamma. Biochem Biophys Res Commun, 1988. 155(1): p. 429–35.
Dunn, G.P., et al., A critical function for type I interferons in cancer immunoediting. Nat Immunol, 2005. 6(7): p. 722–9.
Greenberg, H.B., et al., Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med, 1976. 295(10): p. 517–22.
Krown, S.E., et al., Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N Engl J Med, 1983. 308(18): p. 1071–6.
Talpaz, M., et al., Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol, 1986. 64(1): p. 87–95.
Harris, J.M., N.E. Martin, and M. Modi, Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet, 2001. 40(7): p. 539–51.
Reddy, K.R., Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis, 2004. 24(Suppl 2): p. 33–8.
Youngster, S., et al., Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des, 2002. 8(24): p. 2139–57.
Motzer, R.J., et al., Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol, 2002. 13(11): p. 1799–805.
Talpaz, M., et al., Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood, 2001. 98(6): p. 1708–13.
Nagai, M. and T. Arai, Clinical effect of interferon in malignant brain tumours. Neurosurg Rev, 1984. 7(1): p. 55–64.
Bukowski, R.M., et al., Phase I trial of natural human interferon beta in metastatic malignancy. Cancer Res, 1991. 51(3): p. 836–40.
Aulitzky, W.E., et al., Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia. Ann Hematol, 1993. 67(5): p. 205–11.
Carnaud, C., et al., Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol, 1999. 163(9): p. 4647–50.
Frucht, D.M., et al., IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol, 2001. 22(10): p. 556–60.
Harris, D.P., et al., Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol, 2000. 1(6): p. 475–82.
Yoshimoto, T., et al., IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol, 1998. 161(7): p. 3400–7.
Boehm, U., et al., Cellular responses to interferon-gamma. Annu Rev Immunol, 1997. 15: p. 749–95.
Freedman, A.S., et al., Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol, 1991. 137(2): p. 429–37.
Wallach, D., M. Fellous, and M. Revel, Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature, 1982. 299(5886): p. 833–6.
Groettrup, M., et al., Interferon-gamma inducible exchanges of 20S proteasome active site subunits: why? Biochimie, 2001. 83(3–4): p. 367–72.
Groettrup, M., et al., A third interferon-gamma-induced subunit exchange in the 20S proteasome. Eur J Immunol, 1996. 26(4): p. 863–9.
Hisamatsu, H., et al., Newly identified pair of proteasomal subunits regulated reciprocally by interferon gamma. J Exp Med, 1996. 183(4): p. 1807–16.
Gajewski, T.F. and F.W. Fitch, Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol, 1988. 140(12): p. 4245–52.
Snapper, C.M. and W.E. Paul, Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science, 1987. 236(4804): p. 944–7.
Dighe, A.S., et al., Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity, 1994. 1(6): p. 447–56.
Coughlin, C.M., et al., Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity, 1998. 9(1): p. 25–34.
Friesel, R., A. Komoriya, and T. Maciag, Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol, 1987. {104}(3): p. 689–96.
Pfizenmaier, K., et al., Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. Cancer Res, 1985. {45}(8): p. 3503–9.
Ratliff, T.L., et al., Inhibition of mouse bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta. Cancer Res, 1984. {44}(10): p. 4377–81.
Rubin, B.Y., V. Sekar, and W.A. Martimucci, Comparative antiproliferative efficacies of human alpha and gamma interferons. J Gen Virol, 1983. {64}(8): p. 1743–8.
Elhilali, M.M., et al., Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. BJU Int, 2000. {86}(6): p. 613–8.
Koziner, B., et al., Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation. Acta Haematol, 2002. {108}(2): p. 66–73.
Small, E.J., et al., The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am, 1998. {4}(3): p. 162–7.
Todd, P.A. and K.L. Goa, Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. Drugs, 1992. {43}(1): p. 111–22.
Golomb, H.M., et al., Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol, 1986. {4}(6): p. 900–5.
Quesada, J.R., et al., Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood, 1986. {68}(2): p. 493–7.
Golomb, H.M., et al., Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983–1986. Leukemia, 1992. {6}(11): p. 1177–80.
Dadmarz, R., et al., The mechanism of action of interferon-alpha (IFN-alpha) in hairy-cell leukaemia; Hu-IFN-alpha 2 receptor expression by hairy cells and other normal and leukaemic cell types. Leuk Res, 1986. {10}(11): p. 1279–85.
Paganelli, K.A., et al., B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. Blood, 1986. {67}(4): p. 937–42.
Huber, C., et al., Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia. Leukemia, 1987. {1}(4): p. 355–7.
Goodman, G.R., et al., Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol, 2003. {21}(5): p. 891–6.
Seymour, J.F., et al., Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia, 1995. {9}(5): p. 929–32.
Talpaz, M., et al., Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med, 1986. {314}(17): p. 1065–9.
Talpaz, M., et al., Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood, 1983. {62}(3): p. 689–92.
The Italian Cooperative Study Group on Chronic Myeloid Leukemia, Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med, 1994. {330}(12): p. 820–5.
Allan, N.C., S.M. Richards, and P.C. Shepherd, UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet, 1995. {345}(8962): p. 1392–7.
Broustet, A., et al., Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study. Eur J Cancer, 1991. {27}(Suppl 4): p. S18–21.
Hehlmann, R., et al., Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood, 1994. {84}(12): p. 4064–77.
Ohnishi, K., et al., A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood, 1995. {86}(3): p. 906–16.
The Italian Cooperative Study Group on Chronic Myeloid Leukemia, Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood, 1998. {92}(5): p. 1541–8.
Hehlmann, R., et al., Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia, 2003. {17}(8): p. 1529–37.
Chronic Myeloid Leukemia Trialists’ Collaborative Group, Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst, 1997. {89}(21): p. 1616–20.
Yasukawa, M., et al., CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood, 1998. {92}(9): p. 3355–61.
Aswald, J.M., J.H. Lipton, and H.A. Messner, Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia. Cytokines Cell Mol Ther, 2002. {7}(2): p. 75–82.
Nicolson, N.L., M. Talpaz, and G.L. Nicolson, Interferon-alpha directly inhibits DNA polymerase activity in isolated chromatin nucleoprotein complexes: correlation with IFN-alpha treatment outcome in patients with chronic myelogenous leukemia. Gene, 1995. {159}(1): p. 105–11.
Kuhr, T., et al., A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res, 2003. {27}(5): p. 405–11.
Giles, F.J., et al., A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study. Leuk Lymphoma, 2000. {37}(3–4): p. 367–77.
Guilhot, F., et al., Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med, 1997. {337}(4): p. 223–9.
Anstrom, K.J., et al., Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004. {101}(11): p. 2584–92.
O’Brien, S.G. and M.W. Deininger, Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol, 2003. {40}(2): p. 26–30.
Kantarjian, H.M., et al., Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer, 2003. {98}(12): p. 2636–42.
Branford, S., et al., Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 2003. {17}(12): p. 2401–9.
Foon, K.A., et al., Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med, 1984. {311}(18): p. 1148–52.
Siegert, W., et al., Treatment of non-hodgkin’s lymphoma of low-grade malignancy with human fibroblast interferon. Anticancer Res, 1982. {2}(4): p. 193–8.
Louie, A.C., et al., Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. Blood, 1981. {58}(4): p. 712–8.
Solal-Celigny, P., et al., Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol, 1998. {16}(7): p. 2332–8.
Solal-Celigny, P., et al., Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. N Engl J Med, 1993. {329}(22): p. 1608–14.
Rohatiner, A.Z., et al., Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol, 2005. {23}(10): p. 2215–23.
Fisher, R.I., et al., Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin’s lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol, 2000. {18}(10): p. 2010–6.
Barnetson, R.S. and G.M. Halliday, Regression in skin tumours: a common phenomenon. Australas J Dermatol, 1997. {38}(Suppl 1): p. S63–5.
Chang, P. and W.H. Knapper, Metastatic melanoma of unknown primary. Cancer, 1982. {49}(6): p. 1106–11.
Panagopoulos, E. and D. Murray, Metastatic malignant melanoma of unknown primary origin: a study of 30 cases. J Surg Oncol, 1983. {23}(1): p. 8–10.
Norman, J., et al., Metastatic melanoma with an unknown primary. Ann Plast Surg, 1992. {28}(1): p. 81–4.
Reintgen, D.S., et al., Metastatic malignant melanoma with an unknown primary. Surg Gynecol Obstet, 1983. {156}(3): p. 335–40.
Gromet, M.A., W.L. Epstein, and M.S. Blois, The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer, 1978. {42}(5): p. 2282–92.
Baab, G.H. and C.M. McBride, Malignant melanoma: the patient with an unknown site of primary origin. Arch Surg, 1975. {110}(8): p. 896–900.
King, M., D. Spooner, and D.C. Rowlands, Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: a case report and a review of the literature. Clin Oncol (R Coll Radiol), 2001. {13}(6): p. 466–9.
Coates, A., et al., Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma. J Interferon Res, 1986. {6}(1): p. 1–4.
Creagan, E.T., et al., Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer, 1984. {54}(12): p. 2844–9.
Dorval, T., et al., Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma. Cancer, 1986. {58}(2): p. 215–8.
Hersey, P., et al., Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer, 1985. {51}(6): p. 815–26.
Mughal, T.I., et al., Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma. J Cancer Res Clin Oncol, 1988. {114}(1): p. 108–9.
Neefe, J.R., et al., Phase II study of recombinant alpha-interferon in malignant melanoma. Am J Clin Oncol, 1990. {13}(6): p. 472–6.
Robinson, W.A., et al., Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology, 1986. {172}(3–5): p. 275–82.
Sertoli, M.R., et al., Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. Oncology, 1989. {46}(2): p. 96–8.
Steiner, A., C. Wolf, and H. Pehamberger, Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol, 1987. {113}(5): p. 459–65.
Decatris, M., S. Santhanam, and K. O’Byrne, Potential of interferon-alpha in solid tumours: part 1. BioDrugs, 2002. {16}(4): p. 261–81.
Legha, S.S., et al., Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol, 1987. {5}(8): p. 1240–6.
Falkson, C.I., et al., Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol, 1998. {16}(5): p. 1743–51.
Creagan, E.T., et al., Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma. Analysis of complete and long-term responding patients. Cancer, 1986. {58}(12): p. 2576–8.
Eggermont, A.M., et al., Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet, 2005. {366}(9492): p. 1189–96.
Grob, J.J., et al., Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet, 1998. {351}(9120): p. 1905–10.
Castello, G., et al., Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res, 1993. {3}(1): p. 43–9.
Creagan, E.T., et al., Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol, 1995. {13}(11): p. 2776–83.
Kleeberg, U.R., et al., Final results of the EORTC 18871/DKG 80–1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer, 2004. {40}(3): p. 390–402.
Pehamberger, H., et al., Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol, 1998. {16}(4): p. 1425–9.
Cameron, D.A., et al., Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer, 2001. {84}(9): p. 1146–9.
Hancock, B.W., et al., Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol, 2004. {22}(1): p. 53–61.
Kirkwood, J.M., et al., High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol, 2001. {19}(9): p. 2370–80.
Kirkwood, J.M., et al., High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol, 2000. {18}(12): p. 2444–58.
Hillner, B.E., et al., Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol, 1997. {15}(6): p. 2351–8.
Kirkwood, J.M., et al., Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol, 1996. {14}(1): p. 7–17.
Kirkwood, J.M., et al., A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res, 2004. {10}(5): p. 1670–7.
Falkson, C.I., G. Falkson, and H.C. Falkson, Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol, 1991. {9}(8): p. 1403–8.
Thomson, D.B., et al., Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial. Melanoma Res, 1993. {3}(2): p. 133–8.
Bajetta, E., et al., Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol, 1994. {12}(4): p. 806–11.
Creagan, E.T., et al., A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma. Cancer, 1988. {62}(12): p. 2472–4.
deKernion, J.B., et al., The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol, 1983. {130}(6): p. 1063–6.
Quesada, J.R., D.A. Swanson, and J.U. Gutterman, Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report. J Clin Oncol, 1985. {3}(8): p. 1086–92.
Quesada, J.R., et al., Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol, 1985. {3}(11): p. 1522–8.
Kempf, R.A., et al., Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma. J Biol Response Mod, 1986. {5}(1): p. 27–35.
Umeda, T. and T. Niijima, Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer, 1986. {58}(6): p. 1231–5.
Trump, D.L., et al., High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study. Cancer Treat Rep, 1987. {71}(2): p. 165–9.
Muss, H.B., et al., Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol, 1987. {5}(2): p. 286–91.
Porzsolt, F., et al., Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial. J Cancer Res Clin Oncol, 1988. {114}(1): p. 95–100.
Steineck, G., et al., Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol, 1990. {29}(2): p. 155–62.
Minasian, L.M., et al., Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol, 1993. {11}(7): p. 1368–75.
Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet, 1999. {353}(9146): p. 14–7.
Kirkwood, J.M., et al., A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res, 1985. {45}(2): p. 863–71.
Flanigan, R.C., et al., Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med, 2001. {345}(23): p. 1655–9.
Pizzocaro, G., et al., Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol, 2001. {19}(2): p. 425–31.
Kriegmair, M., R. Oberneder, and A. Hofstetter, Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology, 1995. {45}(5): p. 758–62.
Fossa, S.D., et al., Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol, 1992. {3}(4): p. 301–5.
Nanus, D.M., et al., Interaction of retinoic acid and interferon in renal cancer cell lines. J Interferon Cytokine Res, 2000. {20}(9): p. 787–94.
Motzer, R.J., et al., Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol, 2000. {18}(16): p. 2972–80.
Foon, K., et al., A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod, 1988. {7}(6): p. 540–5.
De Mulder, P.H., et al., EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer, 1995. {71}(2): p. 371–5.
Schalling, M., et al., A role for a new herpes virus (KSHV) in different forms of Kaposi’s sarcoma. Nat Med, 1995. {1}(7): p. 707–8.
Sinkovics, J.G., Kaposi’s sarcoma: its ‘oncogenes’ and growth factors. Crit Rev Oncol Hematol, 1991. {11}(2): p. 87–107.
Ensoli, B., et al., AIDS-Kaposi’s sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science, 1989. {243}(4888): p. 223–6.
Folkman, J., Successful treatment of an angiogenic disease. N Engl J Med, 1989. {320}(18): p. 1211–2.
White, C.W., et al., Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med, 1989. {320}(18): p. 1197–200.
Ezekowitz, A., J. Mulliken, and J. Folkman, Interferon alpha therapy of haemangiomas in newborns and infants. Br J Haematol, 1991. {79}(1): p. 67–8.
Real, F.X., H.F. Oettgen, and S.E. Krown, Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol, 1986. {4}(4): p. 544–51.
Gelmann, E.P., et al., Human lymphoblastoid interferon treatment of Kaposi’s sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. Am J Med, 1985. {78}(5): p. 737–41.
Groopman, J.E., et al., Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med, 1984. {100}(5): p. 671–6.
Mauss, S. and H. Jablonowski, fficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi’s sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol, 1995. {10}(2): p. 157–62.
Krown, S.E., et al., Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med, 1990. {112}(11): p. 812–21.
Dezube, B.J., L. Pantanowitz, and D.M. Aboulafia, Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read, 2004. {14}(5): p. 236–8, 243–4, 251–3.
Jonasch, E. and F.G. Haluska, Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist, 2001. {6}(1): p. 34–55.
Greenberg, D.B., et al., Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer, 2000. {v>89}(2): p. 356–62.
Musselman, D.L., et al., Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med, 2001. {344}(13): p. 961–6.
Jonasch, E., et al., Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J, 2000. {6}(3): p. 139–45.
Lacotte, L., et al., Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia. Acta Haematol, 2000. {102}(3): p. 160–2.
Ravandi-Kashani, F., et al., Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect? Cancer, 1999. {85}(12): p. 2583–8.
Rachmani, R., et al., Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients. Acta Haematol, 1998. {100}(4): p. 204–6.
Iyoda, K., et al., Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C. J Gastroenterol, 1998. {33}(4): p. 588–92.
Gentile, I., et al., Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit. J Interferon Cytokine Res, 2005. {25}(5): p. 283–5.
Braathen, L.R. and P. Stavem, Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides. BMJ, 1989. {298}(6689): p. 1713.
Pangalis, G.A. and E. Griva, Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report. Cancer, 1988. {61}(5): p. 869–72.
Akard, L.P., et al., Alpha-interferon and immune hemolytic anemia. Ann Intern Med, 1986. {105}(2): p. 306.
Jones, T.H., S. Wadler, and K.H. Hupart, Endocrine-mediated mechanisms of fatigue during treatment with interferon-alpha. Semin Oncol, 1998. {25}(1): p. 54–63.
Brudin, L.H., et al., Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med, 1994. {21}(4): p. 297–305.
Lewis, P.J. and A. Salama, Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med, 1994. {35}(10): p. 1647–9.
Brenard, R., Practical management of patients treated with alpha interferon. Acta Gastroenterol Belg, 1997. {60}(3): p. 211–3.
Dalekos, G.N., et al., A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol, 1998. {10}(11): p. 933–9.
Gogas, H., et al., Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med, 2006. {354}(7): p. 709–18.
Waldmann, T.A. and M. Tsudo, Interleukin-2 receptors: biology and therapeutic potentials. Hosp Pract (Off Ed), 1987. {22}(1): p. 77–84, 93–4.
Chan, W.C., et al., Large granular lymphocyte proliferation: an analysis of T-cell receptor gene arrangement and expression and the effect of in vitro culture with inducing agents. Blood, 1988. {71}(1): p. 52–8.
Begley, C.G., et al., Human B lymphocytes express the p75 component of the interleukin 2 receptor. Leuk Res, 1990. {14}(3): p. 263–71.
Mingari, M.C., et al., Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature, 1984. {312}(5995): p. 641–3.
Sakaguchi, S., et al., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995. {155}(3): p. 1151–64.
Golgher, D., et al., Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol, 2002. {32}(11): p. 3267–75.
Barmeyer, C., et al., The interleukin-2-deficient mouse model. Pathobiology, 2002. {70}(3): p. 139–42.}
Baumgart, D.C., et al., Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice. Cell Immunol, 1998. {187}(1): p. 52–66.
Garrelds, I.M., et al., Interleukin-2-Deficient mice: effect on cytokines and inflammatory cells in chronic colonic disease. Dig Dis Sci, 2002. {47}(3): p. 503–10.
Kung, J.T., D. Beller, and S.T. Ju, Lymphokine regulation of activation-induced apoptosis in T cells of IL-2 and IL-2R beta knockout mice. Cell Immunol, 1998. {185}(2): p. 158–63.
Negrier, S., et al., Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol, 1989. {25}(Suppl 3): p. S21–8.
Topalian, S.L., et al., Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol, 1988. {6}(5): p. 839–53.
Rosenberg, S.A., et al., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med, 1985. {313}(23): p. 1485–92.
Fisher, R.I., S.A. Rosenberg, and G. Fyfe, Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am, 2000. {6}(Suppl 1): p. S55–7.
Fyfe, G.A., et al., Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol, 1996. {14}(8): p. 2410–1.
Yang, J.C., et al., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol, 2003. {21}(16): p. 3127–32.
Atzpodien, J., et al., Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha. Ann Oncol, 1990. {1}(5): p. 377–8.
Figlin, R.A., et al., Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol, 1992. {10}(3): p. 414–21.
Veelken, H., et al., Combination of interleukin-2 and interferon-alpha in renal cell carcinoma and malignant melanoma: a phase II clinical trial. Biotechnol Ther, 1992. {3}(1–2): p. 1–14.
Atzpodien, J., et al., Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol, 2004. {22}(7): p. 1188–94.
McDermott, D.F., et al., Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol, 2005. {23}(1): p. 133–41.
Atkins, M.B., et al., High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am, 2000. {6}(Suppl 1): p. S11–4.
Atkins, M.B., Cytokine-based and biochemotherapy for advanced melanoma. Clin Cancer Res, 2006. {12}(7 Pt 2): p. 2353s–8s.
Rosenberg, S.A., et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med, 1998. {4}(3): p. 321–7.
Rosenberg, S.A., et al., Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol, 1999. {163}(3): p. 1690–5.
Gollob, J., L. Flaherty, and J. Smith. A Cytokine Working Group (CWG) phase II trial of a modified gp100 melanoma peptide (gp100 (209M)) and high dose interleukin-2 (HD IL-2) administered q3 weeks in patients with stage IV melanoma: limited antitumor activity. Prog Proc Am Soc Clin Oncol, 2001, abstr 1423.
Rosenberg, S.A., et al., Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol, 1989. {7}(12): p. 1863–74.
Kruit, W.H., et al., Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma. Br J Cancer, 1996. {74}(6): p. 951–5.
Sparano, J.A., et al., Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol, 1993. {11}(10): p. 1969–77.
Feun, L., et al., Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma. Cancer Invest, 2005. {23}(1): p. 3–8.
Atkins, M.B., et al., A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res, 2002. {8}(10): p. 3075–81.
McDermott, D.F., et al., A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res, 2000. {6}(6): p. 2201–8.
Gibbs, P., et al., A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res, 2000. {10}(2): p. 171–9.
Johnston, S.R., et al., Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer, 1998. {77}(8): p. 1280–6.
Eton, O., et al., Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol, 2002. {20}(8): p. 2045–52.
Hauschild, A., et al., Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer, 2001. {84}(8): p. 1036–42.
Rosenberg, S.A., et al., Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol, 1999. {17}(3): p. 968–75.
Atkins, M.B., et al., A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. ASCO Annual Meeting Proceedings, 2003: p. 2847.
O’Day, S.J., et al., Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res, 2002. {8}(9): p. 2775–81.
O’Day, S., et al., A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM). ASCO Annual Meetings Proceedings, 2005. {23}(Suppl 16): p. 7503.
Schwartz, R.N., L. Stover, and J. Dutcher, Managing toxicities of high-dose interleukin-2. Oncology, 2002. {16}(11 Suppl 13): p. 11–20.
Klempner, M.S., et al., An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med, 1990. {322}(14): p. 959–65.
Tilg, H., et al., Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. Cytokine, 1994. {6}(2): p. 215–9.
Tilg, H., et al., Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera. J Immunol, 1993. {151}(6): p. 3299–307.
Margolin, K., et al., Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin Cancer Res, 1997. {3}(4): p. 565–72.
Du Bois, J.S., et al., Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol, 1997. {15}(3): p. 1052–62.
Atkins, M.B., et al., A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Clin Cancer Res, 2001. {7}(3): p. 486–92.
Kilbourn, R.G., et al., Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine. Cancer J Sci Am, 2000. {6}(Suppl 1): p. S21–30.
Kilbourn, R.G., et al., NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. Crit Care Med, 1995. {23}(6): p. 1018–24.
Trinchieri, G., Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol, 2003. {3}(2): p. 133–46.
Bermudez, L.E., M. Wu, and L.S. Young, Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect Immun, 1995. {63}(10): p. 4099–104.
Kaufmann, S.H., C.H. Ladel, and I.E. Flesch, T cells and cytokines in intracellular bacterial infections: experiences with Mycobacterium bovis BCG. Ciba Found Symp, 1995. {195}: p. 123–32; discussion 132–6.
Reis e Sousa, C., et al., In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J Exp Med, 1997. {186}(11): p. 1819–29.
Coutelier, J.P., J. Van Broeck, and S.F. Wolf, Interleukin-12 gene expression after viral infection in the mouse. J Virol, 1995. {69}(3): p. 1955–8.
Kobayashi, M., et al., Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med, 1989. {170}(3): p. 827–45.}
Kubin, M., M. Kamoun, and G. Trinchieri, Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med, 1994. {180}(1): p. 211–22.
Perussia, B., et al., Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells. J Immunol, 1992. {149}(11): p. 3495–502.
Manetti, R., et al., Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med, 1993. {177}(4): p. 1199–204.
Satoh, Y., et al., Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol, 2002. {2}(6): p. 337–49.
Mazzolini, G., et al., Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther, 1999. {6}(6): p. 514–22.
Gao, J.Q., et al., A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma. Biochem Biophys Res Commun, 2005. {328}(4): p. 1043–50.
Bramson, J.L., et al., Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther, 1996. {7}(16): p. 1995–2002.
Kodama, T., et al., Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol, 1999. {29}(4): p. 1390–6.
Smyth, M.J., et al., NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med, 2004. {200}(10): p. 1325–35.
Kawamura, T., et al., Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol, 1998. {160}(1): p. 16–9.
Boggio, K., et al., Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med, 1998. {188}(3): p. 589–96.
Gollob, J.A., et al., Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res, 2000. {6}(5): p. 1678–92.
Okamura, H., et al., Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature, 1995. {378}(6552): p. 88–91.
Micallef, M.J., et al., Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol, 1996. {26}(7): p. 1647–51.
Tsutsui, H., et al., IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol, 1997. {159}(8): p. 3961–7.
Tomura, M., et al., A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3- cells. J Immunol, 1998. {160}(10): p. 4738–46.
Hunter, C.A., et al., Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer. Eur J Immunol, 1997. {27}(11): p. 2787–92.
Hoshino, K., et al., The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med, 1999. {190}(10): p. 1541–8.
Tsutsui, H., et al., IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol, 1996. {157}(9): p. 3967–73.
Dao, T., et al., Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol, 1996. {173}(2): p. 230–5.
Park, C.C., et al., Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 2001. {167}(3): p. 1644–53.
Coughlin, C.M., et al., Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest, 1998. {101}(6): p. 1441–52.
Paulukat, J., et al., Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol, 2001. {167}(12): p. 7038–43.
Novick, D., et al., Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity, 1999. {10}(1): p. 127–36.
Robertson, M.J., et al., Phase I study of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions every 28 days in patients with solid tumors. ASCO Annual Meeting Proceedings, 2005: p. 2513.
Koch, K.M., et al., PK and PD of recombinant human IL-18 (rhIL-18) administered IV in repeated cycles to patients with solid tumors. ASCO Annual Meeting Proceedings, 2005: p. 2535.
Lewis, N., et al., Phase I dose escalation study to assess tolerability and pharmacokinetics of recombinant human IL-18 (rhIL-18) administered as fourteen daily subcutaneous injections in patients with solid tumors. ASCO Annual Meeting Proceedings, 2004: p. 2591.
Parrish-Novak, J., et al., Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 2000. {408}(6808): p. 57–63.
Brandt, K., et al., Interleukin-21 inhibits dendritic cell activation and maturation. Blood, 2003. {102}(12): p. 4090–8.
Suto, A., et al., Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells. Blood, 2002. {100}(13): p. 4565–73.
Pene, J., et al., Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J Immunol, 2004. {172}(9): p. 5154–7.
Habib, T., A. Nelson, and K. Kaushansky, IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol, 2003. {112}(6): p. 1033–45.
Wang, G., et al., In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res, 2003. {63}(24): p. 9016–22.
Ugai, S., et al., Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther, 2003. {10}(10): p. 771–8.
Ugai, S., et al., Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther, 2003. {10}(3): p. 187–92.
Takaki, R., et al., IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol, 2005. {175}(4): p. 2167–73.
Moroz, A., et al., IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol, 2004. {173}(2): p. 900–9.
Ma, H.L., et al., IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol, 2003. {171}(2): p. 608–15.
Kishida, T., et al., Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther, 2003. {8}(4): p. 552–8.
Curti, B.D., et al., Preliminary tolerability and anti-tumor activity of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma. ASCO Annual Meeting Proceedings, 2005: p. 2502.
Dranoff, G., et al., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA, 1993. {90}(8): p. 3539–43.
Grabstein, K.H., et al., Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science, 1986. {232}(4749): p. 506–8.
Yamasaki, S., et al., Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol Immunother, 1995. {40}(4): p. 268–71.
Hanada, K., R. Tsunoda, and H. Hamada, GM-CSF-induced in vivo expansion of splenic dendritic cells and their strong costimulation activity. J Leukoc Biol, 1996. {60}(2): p. 181–90.
Armstrong, C.A., et al., Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res, 1996. {56}(9): p. 2191–8.
Mach, N., et al., Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res, 2000. {60}(12): p. 3239–46.
Hu, H.M., et al., Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol, 2000. {165}(8): p. 4246–53.
Ridolfi, L. and R. Ridolfi, Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology, 2002. {49}(44): p. 335–9.
Vaquerano, J.E., et al., Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factor. Arch Dermatol, 1999. {135}(10): p. 1276–7.
Si, Z., P. Hersey, and A.S. Coates, Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res, 1996. {6}(3): p. 247–55.
Dranoff, G., GM-CSF-secreting melanoma vaccines. Oncogene, 2003. {22}(20): p. 3188–92.
Spitler, L.E., et al., Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol, 2000. {18}(8): p. 1614–21.
Dunn, G.P., L.J. Old, and R.D. Schreiber, The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 2004. {21}(2): p. 137–48.
Rivoltini, L., et al., Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev, 2002. {188}: p. 97–113.
De Paola, F., et al., Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2. Br J Cancer, 2003. {88}(2): p. 320–6.
Bukowski, R.M., et al., Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res, 1998. {4}(10): p. 2337–47.
Piancatelli, D., et al., Local expression of cytokines in human colorectal carcinoma: evidence of specific interleukin-6 gene expression. J Immunother, 1999. {22}(1): p. 25–32.
Lissoni, P., et al., Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors. J Biol Regul Homeost Agents, 1995. {9}(4): p. 146–9.
Chen, C.K., et al., T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies. J Formos Med Assoc, 1999. {98}(1): p. 24–30.
Nemunaitis, J., et al., Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest, 2001. {19}(3): p. 239–47.
Chen, Q., et al., Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer, 1994. {56}(5): p. 755–60.
Kim, R., et al., Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res, 2006. {66}(11): p. 5527–36.
Smyth, M.J. and D.I. Godfrey, NKT cells and tumor immunity–a double-edged sword. Nat Immunol, 2000. {1}(6): p. 459–60.
Yanagisawa, K., et al., Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide. J Immunol, 2002. {168}(12): p. 6494–9.
van der Vliet, H.J., et al., Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res, 2003. {63}(14): p. 4101–6.
Tahir, S.M., et al., Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol, 2001. {167}(7): p. 4046–50.
Dhodapkar, M.V., et al., A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med, 2003. {197}(12): p. 1667–76.
Viguier, M., et al., Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol, 2004. {173}(2): p. 1444–53.
Marshall, N.A., et al., Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood, 2004. {103}(5): p. 1755–62.
Akasaki, Y., et al., Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol, 2004. {173}(7): p. 4352–9.
Cesana, G.C., et al., Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol, 2006. {24}(7): p. 1169–77.
Tomura, M., et al., A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol, 1999. {163}(1): p. 93–101.
Kitamura, H., et al., The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)- 12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med, 1999. {189}(7): p. 1121–8.
Chang, D.H., et al., Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med, 2005. {201}(9): p. 1503–17.
Fujii, S., et al., Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol, 2002. {3}(9): p. 867–74.
Barnett, B., et al. Depleting CD4+ CD25+ Regulatory T-cells improves immunity in cancer-bearing patients. Proceedings of AACR, 2004.
Vieweg, J., Z. Su, and J. Dannuli. Enhancement of antitumor immunity following depletion of CD+CD25+ regulatory T-cells. Proceedings of ASCO, 2004.
Dudley, M.E., et al., A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother, 2002. {25}(3): p. 243–51.
Dudley, M.E., et al., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 2002. {298}(5594): p. 850–4.
Phan, G.Q., et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA, 2003. {100}(14): p. 8372–7.
Reuben, J.M., et al., Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer, 2006. {106}(11): p. 2437–44.
Ribas, A., et al., Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol, 2005. {23}(35): p. 8968–77.
Maker, A.V., et al., Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol, 2005. {12}(12): p. 1005–16.
Upton, M.P., et al., Histologic predictors of renal cell carcinoma (RCC) response to interleukin-2-based therapy. ASCO Annual Meeting Proceedings, 2004: p. 3420.
Bui, M.H., et al., Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res, 2004. {9}(2): p. 802–11.
Atkins, M., et al., Carbonic Anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. ASCO Annual Meeting Proceedings, 2004. p. 4512.
Scheibenbogen, C., et al., HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res, 1994. {4}(3): p. 191–4.
Tartour, E., et al., Predictors of clinical response to interleukin-2–based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol, 1996. {14}(5): p. 1697–703.
Liu, D., et al., Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res, 2005. {11}(3): p. 1237–46.
Garcia-Hernandez, M.L., et al., Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology, 2002. {105}(2): p. 231–43.
Huang, S., et al., Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res, 1996. 2(12): p. 1969–79.
Howell, W.M., et al., IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun, 2001. {2}(1): p. 25–31.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press
About this chapter
Cite this chapter
Koon, H.B., B.Atkins, M. (2008). Cytokine-Based Therapy for Cancer. In: Kaufman, H.L., Wadler, S., Antman, K. (eds) Molecular Targeting in Oncology. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-337-0_20
Download citation
DOI: https://doi.org/10.1007/978-1-59745-337-0_20
Publisher Name: Humana Press
Print ISBN: 978-1-58829-577-4
Online ISBN: 978-1-59745-337-0
eBook Packages: MedicineMedicine (R0)